Epigenomics AG Stock price Deutsche Boerse AG

Equities

ECX

DE000A11QW50

Biotechnology & Medical Research

End-of-day quote Deutsche Boerse AG 06:00:00 2024-02-04 pm EST 5-day change 1st Jan Change
1.785 EUR -1.92% Intraday chart for Epigenomics AG +9.51% -4.03%
Sales 2024 * 150K 162K Sales 2025 * - Capitalization 1.62M 1.75M
Net income 2024 * - 0 Net income 2025 * - 0 EV / Sales 2024 * -3.47 x
Net cash position 2024 * 2.14M 2.31M Net cash position 2025 * 1.69M 1.83M EV / Sales 2025 * -
P/E ratio 2024 *
-2.77 x
P/E ratio 2025 *
-2.79 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 66.43%
More Fundamentals * Assessed data
Dynamic Chart
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.86 EUR
Average target price
16.85 EUR
Spread / Average Target
+805.91%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Epigenomics AG
  4. Stock Epigenomics AG - Deutsche Boerse AG